Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

• QCOM stock dropped 48.2% from a high of $56.37 on August 15, 2008, to $29.21 on November 20, 2008, compared to a peak-to-trough decline of 56.8% for the S&P 500 • The stock completely ...

Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits ...

Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a ...

Key Points Energy, healthcare, and chip stocks have driven the market higher today. Tesla has stopped falling and has recovered slightly due to the Musk-Trump feud cooling down. Many stocks have made ...

Eli Lilly and Company (LLY)’s share was trading at $765.68 as of 5 th June. LLY’s trailing and forward P/E were 62.30 and 35.09 respectively according to Yahoo Finance.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an ...

Lilly to pay $290 million upfront and as much as $580 million in sales-based milestones and royalties. Camurus and Lilly have entered a collaboration and license agreement, granting Lilly exclusive, ...